Sunshine Biopharma Inc. Reports 2025 Financial Results

Sunshine Biopharma Inc. reported its financial results for the fiscal year ended December 31, 2025. The company generated $36.3 million in revenue, a 4.1% increase from the previous year. They also raised $2.46 million through a direct offering to support sales operations and launched nine new generic prescription drugs across various therapeutic areas. A key development was the advancement of their proprietary antiviral research, with new protease inhibitors showing promising results in preclinical studies. The company incurred a net loss of $5.98 million for the year, which included a $1.75 million non-cash impairment charge. To improve financial performance, Sunshine Biopharma implemented cost-reduction initiatives in January 2026, aiming to reduce expenses by $2 million to $3 million in 2026 and move towards profitability. The company continues to market generic drugs and advance its proprietary drug development programs in oncology and antivirals.